Overview

Alemtuzumab and Rituximab in Aplastic Anemia

Status:
Withdrawn
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the efficacy of combination of alemtuzumab and rituximab as first line therapy in aplastic anemia.
Phase:
N/A
Details
Lead Sponsor:
Hospital Universitario Dr. Jose E. Gonzalez
Treatments:
Alemtuzumab
Rituximab